BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 17128670)

  • 1. [Neurofibromatosis type 2 (central neurofibromatosis or bilateral acoustic neuromas, vestibular schwannomas): from phenotype to gene].
    Sabol Z; Kipke-Sabol L; Miklić P; Hajnsek-Propadalo S; Sabol F
    Lijec Vjesn; 2006; 128(9-10):309-16. PubMed ID: 17128670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neurofibromatosis type 2 (NF2)].
    Araki N; Takeshima H; Saya H
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1427-31. PubMed ID: 9309136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic neurofibromatosis type 2 gene mutations and growth characteristics in vestibular schwannoma.
    Irving RM; Harada T; Moffat DA; Hardy DG; Whittaker JL; Xuereb JH; Maher ER
    Am J Otol; 1997 Nov; 18(6):754-60. PubMed ID: 9391673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients.
    Ruggieri M; Iannetti P; Polizzi A; La Mantia I; Spalice A; Giliberto O; Platania N; Gabriele AL; Albanese V; Pavone L
    Neuropediatrics; 2005 Feb; 36(1):21-34. PubMed ID: 15776319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tumour suppressor protein NF2/merlin: the puzzle continues.
    Hovens CM; Kaye AH
    J Clin Neurosci; 2001 Jan; 8(1):4-7. PubMed ID: 11148074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas.
    Sirén V; Antinheimo JP; Jääskeläinen J; Böhling T; Carpén O; Vaheri A
    Acta Neurochir (Wien); 2004 Feb; 146(2):111-8. PubMed ID: 14963743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [NF2: ocular, neural and genetic manifestations].
    Feucht M; Mautner VF; Richard G
    Klin Monbl Augenheilkd; 2005 Apr; 222(4):312-6. PubMed ID: 15844040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NF2: the wizardry of merlin.
    Xiao GH; Chernoff J; Testa JR
    Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neurofibromatosis].
    Wolkenstein P; Decq P
    Neurochirurgie; 1998 Nov; 44(4):267-72. PubMed ID: 9864698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of the patient and family with neurofibromatosis 2: a consensus conference statement.
    Evans DG; Baser ME; O'Reilly B; Rowe J; Gleeson M; Saeed S; King A; Huson SM; Kerr R; Thomas N; Irving R; MacFarlane R; Ferner R; McLeod R; Moffat D; Ramsden R
    Br J Neurosurg; 2005 Feb; 19(1):5-12. PubMed ID: 16147576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms.
    Ruggieri M; Praticò AD; Evans DG
    Semin Pediatr Neurol; 2015 Dec; 22(4):240-58. PubMed ID: 26706012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular biological analysis of neurofibromatosis type 2 gene].
    Ichimura K; Yuasa Y
    Nihon Rinsho; 1993 Sep; 51(9):2462-6. PubMed ID: 8411729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofibromatosis type 2 in an infant with multiple plexiform schwannomas as first symptom.
    Miyakawa T; Kamada N; Kobayashi T; Hirano K; Fujii K; Sasahara Y; Nagai Y; Shinkai H
    J Dermatol; 2007 Jan; 34(1):60-4. PubMed ID: 17204104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.
    Ruggieri M; Praticò AD; Serra A; Maiolino L; Cocuzza S; Di Mauro P; Licciardello L; Milone P; Privitera G; Belfiore G; Di Pietro M; Di Raimondo F; Romano A; Chiarenza A; Muglia M; Polizzi A; Evans DG
    Acta Otorhinolaryngol Ital; 2016 Oct; 36(5):345-367. PubMed ID: 27958595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofibromatosis type 2.
    Uppal S; Coatesworth AP
    Int J Clin Pract; 2003 Oct; 57(8):698-703. PubMed ID: 14627181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biology of vestibular schwannomas.
    Chang LS; Welling DB
    Methods Mol Biol; 2009; 493():163-77. PubMed ID: 18839347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain.
    Koga H; Araki N; Takeshima H; Nishi T; Hirota T; Kimura Y; Nakao M; Saya H
    Oncogene; 1998 Aug; 17(7):801-10. PubMed ID: 9779996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neurofibromatosis 2 (NF2) tumour suppressor gene: implications beyond the hereditary tumour syndrome?
    Kley N; Seizinger BR
    Cancer Surv; 1995; 25():207-18. PubMed ID: 8718520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma?
    Evans DG; Ramsden RT; Gokhale C; Bowers N; Huson SM; Wallace A
    Clin Genet; 2007 Apr; 71(4):354-8. PubMed ID: 17470137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoblotting analysis of schwannomin/merlin in human schwannomas.
    Harwalkar JA; Lee JH; Hughes G; Kinney SE; Golubić M
    Am J Otol; 1998 Sep; 19(5):654-9. PubMed ID: 9752976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.